It is strongly suggests that the non-glucoregulatory effect of the DPP-4 inhibitor is associated with podocyte protection, whereas the glucoregulatory dose attenuates diabetic nephropathy by decreasing both apoptotic and ROS-mediated injury and by triggering transcriptional activation affording further glycemic control. Here, DPP4 is linked to diabetic kidney disease.